Welcome to our dedicated page for LENSAR SEC filings (Ticker: LNSR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LENSAR, Inc. filings document operating results and material events for a commercial-stage medical device company focused on robotic laser systems for cataract procedures. Form 8-K reports furnish quarterly and annual earnings releases, including disclosures on ALLY system activity, installed-base trends, and recurring revenue components such as procedure, lease, and service revenue.
The company’s filings also record capital and governance matters, including common stock listed on Nasdaq under LNSR, officer transition disclosures, and material agreements such as the Priority Credit Line Agreement. Amendments to material-event reports provide additional detail on credit-line terms, collateral arrangements, interest-rate mechanics, and default provisions.
LENSAR, Inc. Chief Operating Officer Alan B. Connaughton reported a routine insider transaction involving company common stock. On 01/11/2026, 2,262 shares of common stock were withheld by the issuer at a price of $11.57 per share to satisfy tax withholding obligations related to the vesting of restricted stock units, rather than being sold in the open market. Following this tax withholding event, Connaughton beneficially owns 359,461 shares of LENSAR common stock in direct ownership.
LENSAR, Inc. reported Q3 2025 results and provided updates on its pending merger with Alcon. Revenue was $14.3 million (up from $13.5 million), driven by product sales of $11.4 million, lease revenue of $1.6 million, and service revenue of $1.4 million. Operating loss widened to $7.6 million, and net loss was $3.7 million versus $1.5 million a year ago, reflecting higher selling, general and administrative expenses, including $5.3 million in acquisition-related costs this quarter.
Year to date, revenue reached $42.4 million (from $36.8 million) with a net loss of $32.8 million. Cash and cash equivalents were $7.6 million with $9.2 million in short-term investments. Warrant liabilities rose to $43.5 million, contributing a $(13.6) million year-to-date non-cash charge.
Under the Merger Agreement, each share will be converted into $14.00 in cash plus a contingent value right of $2.75 upon achieving 614,000 cumulative procedures between January 1, 2026 and December 31, 2027. The company received a $10.0 million acquisition-related deposit, recorded as a current liability. As of October 24, 2025, common shares outstanding were 11,944,546.
LENSAR, Inc. furnished a press release announcing financial results for the fiscal quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference.
The information in this report, including Exhibit 99.1, is furnished and not deemed filed under Section 18 of the Exchange Act. The filing also includes Exhibit 104, the cover page interactive data file.
LENSAR, Inc. filed its proxy for the 2025 annual meeting, to be held virtually on December 18, 2025 at 11:00 a.m. ET via www.virtualshareholdermeeting.com/LNSR2025. Holders of record as of October 24, 2025 may vote.
Stockholders will vote on: (1) electing Class II directors Nicholas T. Curtis, Todd B. Hammer, and Aimee S. Weisner to terms ending at the 2028 annual meeting; and (2) ratifying PricewaterhouseCoopers LLP as independent registered public accounting firm for 2025. The Board recommends voting FOR all proposals.
As of the record date, there were 11,944,546 shares of common stock and 20,000 shares of Series A Convertible Preferred Stock outstanding and entitled to vote together as a class. Proposal 1 uses plurality voting; Proposal 2 requires a majority of votes cast. Audit fees billed by PwC were $1,086,881 for 2024. The meeting, as contemplated, will occur only if the Merger with Alcon Research, LLC has not been completed by that date.
LENSAR, Inc. announced its 2025 annual meeting of stockholders is scheduled for December 18, 2025 and will be held virtually. Stockholders of record as of the close of business on October 24, 2025 may vote.
The meeting will only occur if the proposed merger with Alcon Research, LLC is not completed before that date. If the merger closes earlier, the company will become a wholly owned subsidiary and the meeting, director nominations, and any stockholder proposals will not be considered.
Deadlines: to be included in the proxy under Rule 14a-8, proposals must be received by October 31, 2025. For other bylaw proposals or director nominations, written notice is due by October 31, 2025. Universal proxy Rule 14a-19 notices are also due by October 31, 2025.
LENSAR (NASDAQ:LNSR) filed additional proxy materials for its pending $14 per-share cash merger with Alcon. The supplement answers shareholder demand letters claiming the May 19 definitive proxy omitted material facts, potentially violating Sections 14(a)/20(a). To pre-empt litigation, LENSAR adds disclosures while denying wrongdoing.
Key additions:
- Confirms no discussions of post-merger employment or equity for executives during Feb 21-26 2025 talks.
- Updates Wells Fargo Securities comps: mean EV/2025E revenue 3.9×, median 2.8×; LENSAR traded at 5.2×.
- WFS selects 4.00-5.25× 2025E and 3.00-4.00× 2026E revenue multiples, implying $12.27–$16.51 per share versus $14.00 cash offer and $16.03 discounted amount.
- Expanded precedent-transaction table (4.0×–6.5× LTM revenue).
The board’s recommendation and the July 2 2025 special-meeting timetable are unchanged.